The macrocyclic tetrapeptide cyclo[Pro-Sar-Phe-d-Phe] is orally bioavailable and blocked both stress- and drug-induced relapse to cocaine and morphine in mice, with fewer side effects than morphine — making it a promising lead for substance abuse treatment.
Oral peptide blocks relapsecyclo[Pro-Sar-Phe-d-Phe] is one of the rare peptides that works when taken by mouth, and it blocked both stress- and drug-induced cocaine and morphine relapse in preclinical models
What the researchers found
Cyclo[Pro-Sar-Phe-d-Phe] was rationally designed based on X-ray and NMR structures of related macrocyclic tetrapeptides. Key pharmacological findings:
- **Orally bioavailable**: The peptide produced antinociception (pain relief) and kappa opioid receptor (KOR) antagonism when given orally in mice.
- **Anti-relapse effects**: Oral administration blocked both stress-induced and drug-induced reinstatement of cocaine and morphine conditioned place preference — the gold-standard preclinical model for relapse.
- **Reduced side effects**: The peptide showed a decreased side-effect profile compared to morphine.
- **Mixed opioid profile**: It acts as an agonist at some opioid receptors while antagonizing kappa opioid receptors, a profile thought to be ideal for treating addiction.
Why it matters
The opioid crisis and cocaine abuse collectively destroy millions of lives, and current treatments for relapse prevention are limited. An orally bioavailable peptide that blocks relapse to multiple drugs of abuse — with fewer side effects than existing opioids — addresses a massive unmet need. The fact that it works against both stress-induced and drug-induced relapse is especially significant, as these are the two main triggers for relapse in humans.
How the study worked
The peptide was rationally designed using structural data from related compounds, synthesized, and characterized. Conformational analysis used NMR spectroscopy and molecular modeling, revealing multiple conformations in polar solvents but a single hydrogen-bond-stabilized conformation in chloroform. Pharmacological testing included the mouse 55°C warm-water tail-withdrawal assay (for pain/opioid activity) and conditioned place preference assays (for cocaine and morphine relapse prevention), all via oral administration.
What this study cannot tell us
All data are from mouse models; oral bioavailability and anti-relapse effects may differ in humans. The specific mechanism of how this peptide prevents relapse (which receptor interactions are most important) was not fully elucidated. Long-term dosing studies and abuse liability assessments were not reported. The conditioned place preference model, while well-established, doesn't fully capture the complexity of human addiction and relapse.
How to read the evidence
This is a preclinical study in mice demonstrating proof-of-concept for a novel peptide compound. The rational design approach and comprehensive pharmacological characterization are rigorous, but the compound is at an early drug development stage with no human data.
When this study was published
Published in 2020, this study is part of ongoing work on macrocyclic tetrapeptide opioid modulators. The substance abuse crisis remains as relevant as ever, keeping this research highly topical.
The bigger picture
Cyclic peptides are gaining traction in drug development because their ring structure resists digestive breakdown, enabling oral delivery — historically peptides' biggest limitation. This study demonstrates that rationally designed macrocyclic peptides can achieve oral bioavailability AND complex pharmacological profiles (mixed agonism/antagonism), opening a new class of potential therapeutics for addiction and pain management.
Questions still open
- Will cyclo[Pro-Sar-Phe-d-Phe] maintain its oral bioavailability and efficacy in larger animals and eventually humans?
- Could this mixed opioid profile approach be used to treat both opioid use disorder and stimulant addiction simultaneously?
- What is the abuse liability of this compound itself, given its partial opioid agonist activity?
Common questions
Why is it unusual for a peptide drug to be taken by mouth?
How does this peptide prevent drug relapse?
Read the original research
Design, Synthesis, and Characterization of the Macrocyclic Tetrapeptide cyclo[Pro-Sar-Phe-d-Phe]: A Mixed Opioid Receptor Agonist-Antagonist Following Oral Administration.
ACS chemical neuroscience, 11(9), 1324-1336
Citation
Ferracane, Michael J; Brice-Tutt, Ariana C; Coleman, Jeremy S; Simpson, Grant G; Wilson, Lisa L; Eans, Shainnel O; Stacy, Heather M; Murray, Thomas F; McLaughlin, Jay P; Aldrich, Jane V. (2020). Design, Synthesis, and Characterization of the Macrocyclic Tetrapeptide cyclo[Pro-Sar-Phe-d-Phe]: A Mixed Opioid Receptor Agonist-Antagonist Following Oral Administration.. ACS chemical neuroscience, 11(9), 1324-1336. https://doi.org/10.1021/acschemneuro.0c00086